RecruitingNot ApplicableNCT05842239

Hyperbaric Oxygen Therapy for Men Suffering From Infertility Due to Oligospermia.

Hyperbaric Oxygen Therapy for Men Suffering From Infertility Due to Oligospermia: a Pilot Study


Sponsor

Assaf-Harofeh Medical Center

Enrollment

15 participants

Start Date

Jan 20, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Infertility in a couple is defined as the inability to achieve conception despite one year of frequent, unprotected intercourse. Infertility affects approximately 12% of couples attempting to conceive. The goal of this study is to explore the potential beneficial effect of HBOT on sperm count of infertile male due to oligospermia.


Eligibility

Sex: MALEMin Age: 21 Years

Inclusion Criteria4

  • Age above 21 years
  • At least two sperm examination showing oligospermia (\<15·106 sperm/mL)
  • Diagnosis of idiopathic oligospermia.
  • Subject willing and able to read, understand and sign an informed consent

Exclusion Criteria10

  • Inability to attend scheduled clinic visits and/or comply with the study protocol
  • Active malignancy
  • Previous treatment with chemotherapy and/or radiation therapy
  • Substance use at baseline
  • Severe or unstable physical disorders or major cognitive deficits at baseline
  • HBOT for any reason prior to study enrolment
  • Chest pathology incompatible with pressure changes (including moderate to severe asthma)
  • Ear or Sinus pathology incompatible with pressure changes
  • Chronic disease like diabetes mellitus, ischemic heart disease etc.
  • Active smoking

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEHyperbaric oxygen therapy

Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes


Locations(1)

The Sagol Center for Hyperbaric Medicine and Research Shamir Medical Center (Assaf Harofeh)

Ẕerifin, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05842239


Related Trials